In October 2019, Vect-Horus and RadioMedix signed a partnership agreement to co- develop a radiotheranostic agent for the diagnosis (Dx) and radiotherapy (Rx) of GBM using Vect-Horus expertise in targeting tumors and RadioMedix know-how in developing radiopharmaceuticals. Under the terms of the collaboration both parties will share the costs of development until Phase 1 (Dx & Rx). The radiotheranostic agent will be then out-licensed to RadioMedix for further clinical development and commercialization.
“GBM is one of the most aggressive human
cancers and new diagnostic probes and targeted therapies are desperately needed
to address this unmet need.” said Dr. Ebrahim
Delpassand, CEO of RadioMedix.
“We are excited to initiate a first in
human exploratory clinical studies of 68Ga-RMX-VH and evaluate the
LDLR-targeting properties of this agent in GBM” said Izabela Tworowska, PhD,
CSO of RadioMedix. “Our long-term-goal is to develop a radiotheranostic drug
for glioblastoma multiforme and expand the treatment options available for GBM
patients.
To
read more please visit:
Source: Business Wire